Company intelligence / Profile preview

IGPH

Hoofddorp, Noord-Holland, Netherlandsigphsolutions.com ↗

Ownership: Private
Development stage: Commercial

Overview

IGEA Pharma commercializes health-tech and med-tech products focused on early detection and risk reduction for life-threatening diseases such as Alzheimer’s disease. Its main product is the ALZ1 at-home lab test kit to measure non-bound copper in the blood—a recognized modifiable risk factor for Alzheimer’s. The company also offers dietary supplements aimed at reducing heavy metals in the bloodstream. There are no reported clinical trial results as its offerings are diagnostics/supplements rather than therapeutics.

Therapeutic areas: OtherEndocrinologyNeurology
Modalities: Diagnostic deviceDietary supplement
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on IGPH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGPH.

Explore the full profile